A Novo Nordisk drug for hypertension and power kidney illness has failed a pivotal examine, a setback for the Danish pharmaceutical big's efforts to supply sufferers a brand new remedy with potential security and efficacy advantages over at present permitted medicine within the class of medicine, together with a product marketed by Bavarians. Novo Nordisk didn’t launch particular particulars about […]